Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors

ChemMedChem

Volumn 7, Issue 9, 2012, Pages 1647-1660

  Bertinaria, Massimo ^a   Shaikh, Mohammed Abrar Abdul Gaffar ^a   Buccellati, Carola ^b   Cena, Clara ^a   Rolando, Barbara ^a   Lazzarato, Loretta ^a   Fruttero, Roberta ^a   Gasco, Alberto ^a   Hoxha, Malvina ^b   Capra, Valérie ^b   Sala, Angelo ^b   Rovati, G Enrico ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cyclooxygenase; Inflammation; Medicinal chemistry; Multitarget drugs; Thromboxane

Indexed keywords

2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLBENZAMIDE; 2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLBENZENE ACETIC ACID; 2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLBENZENE ACETIC ACID METHYL ESTER; 2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLBENZENE ACETONITRILE; 2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLBENZENE METHANOL; 2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLBENZOIC ACID; 2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLBENZOIC ACID METHYL ESTER; 2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] N HYDROXY 5 METHYLBENZENEACETAMIDE; 2 [(2 CHLORO 6 FLUOROPHENYL)METHYLAMINO] 5 METHYLBENZENE; 2 [(2 CHLORO 6 FLUOROPHENYL)METHYLAMINO] 5 METHYLBENZENE ACETONITRILE; 3 [4 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 3 [[[(4 CHLOROPHENYL) SULFONYL]AMINO]METHYL]PHENYL 2 PROPENOIC ACID ETHYL ESTER; 4 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 3 [[[(4 CHLOROPHENYL)SULFONYL]AMINO]METHYL]BENZENEPROPANOIC ACID; 4 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 3 [[[(4 CHLOROPHENYL)SULFONYL]BENZENEPROPANOIC ACID ETHYL ESTER; 4 CHLORO N [[2 [(2 CHLOR 6 FLUOROPHENYL)AMINO] 5 METHYLPHENYL]METHYL]METHANESULFONAMIDE; 4 CHLORO N [[2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 IODOPHENYL]BENZENESULFONAMIDE; 4 CHLORO N [[2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLPHENYL]BENZENESULFONAMIDE; 5 [[2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLPHENYL]METHYL] 1,3,4 OXADIAZOL 2 (3H) ONE; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; LUMIRACOXIB; N (2 CHLORO 6 FLUOROPHENYL) 4 METHYL 2 (1H TETRAZOL 5 YLMETHYL)BENZENAMINE; N [(2 AMINO 5 IODOPHENYL)AMINO] 4 CHLOROBENZENESULFONAMIDE; N [(2 AMINO 5 METHYLPHENYL)AMINO] 4 CHLOROBENZENESULFONAMIDE; N [(2 AMINO 5 METHYLPHENYL)AMINO]METHANESULFONAMIDE; N [2 [2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLPHENYL]ETHYL] 1,1,1 TRIFLUOROMETHANESULFONAMIDE; N [[2 [(2 CHLORO 6 FLUOROPHENYL)AMINO] 5 METHYLPHENYL]METHYL] 1,1,1 TRIFLUOROMETHANESULFONAMIDE; REFECOXIB; TERUTROBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; HEART PROTECTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ADOLESCENT; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; BLOOD PLATELETS; CELL LINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DRUG DESIGN; HUMANS; MALE; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES; THROMBOXANES; YOUNG ADULT;

EID: 84865605796     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201200272     Document Type: Article

References (54)

1. A. L. Blobaum, L. J. Marnett, J. Med. Chem. 2007, 50, 1425-1441.
2. W. L. Smith, D. L. DeWitt, R. M. Garavito, Ann. Rev. Biochem. 2000, 69, 145-182.
3. I. Morita, Prostaglandins Other Lipid Mediators 2002, 68-9, 165-175.
4. W. L. Smith, Trends Biochem. Sci. 2008, 33, 27-37.
5. R. T. V. Schoen, J. Rinald, Am. J. Med. 1989, 86, 449-458.
6. M. M. Wolfe, D. R. Lichtenstein, G. Singh, N. Engl. J. Med. 1999, 340, 1888-1899.
7. M. E. Lane, M.-J. Kim, J. Pharm. Pharmacol. 2006, 58, 1295-1304.
8. Y. J. Lim, J. S. Lee, Y. S. Ku, K. B. Hahm, J. Gastroenterol. Hepatol. 2009, 24, 1169-1178.
9. J. J. Talley, Prog. Med. Chem. 1999, 36, 201-234.
10. X. deLeval, F. Julemont, V. Benoit, M. Frederich, B. Pirotte, J. M. Dogné, Mini-Rev. Med. Chem. 2004, 4, 597-601.
11. P. Singh, A. Mittal, Mini-Rev. Med. Chem. 2008, 8, 73-90.
12. T. Grosser, S. Fries, G. A. FitzGerald, J. Clin. Invest. 2006, 116, 4-15.
13. J. M. Dogné, C. T. Supuran, D. Pratico, J. Med. Chem. 2005, 48, 2251-2257.
14. S. Trelle, S. Reichenbach, S. Wandel, P. Hildebrand, B. Tschannen, P. M. Villiger, M. Egger, P. Juni, BMJ 2011, 342, c7086.
15. P. M. Kearney, C. Baigent, J. Godwin, H. Halls, J. R. Emberson, C. Patrono, BMJ 2006, 332, 1302-1308.
16. T. D. Warner, J. A. Mitchell, Lancet 2008, 371, 270-273.
17. G. A. FitzGerald, N. Engl. J. Med. 2004, 351, 1709-1711.
18. E. M. Antman, D. DeMets, J. Loscalzo, Circulation 2005, 112, 759-770.
19. B. F. McAdam, F. Catella-Lawson, I. A. Mardini, S. Kapoor, J. A. Lawson, G. A. FitzGerald, Proc. Natl. Acad. Sci. USA 1999, 96, 5890-5890.
20. F. Catella-Lawson, B. McAdam, B. W. Morrison, S. Kapoor, D. Kujubu, L. Antes, K. C. Lasseter, H. Quan, B. J. Gertz, G. A. Fitzgerald, J. Pharmacol. Exp. Ther. 1999, 289, 735-741.
21. R. R. Ranatunge, M. Augustyniak, U. K. Bandarage, R. A. Earl, J. L. Ellis, D. S. Garvey, D. R. Janero, L. G. Letts, A. M. Martino, M. G. Murty, S. K. Richardson, J. D. Schroeder, M. J. Shumway, S. W. Tam, A. M. Trocha, D. V. Young, J. Med. Chem. 2004, 47, 2180-2193.
22. K. Chegaev, L. Lazzarato, P. Tosco, C. Cena, E. Marini, B. Rolando, P. A. Carrupt, R. Fruttero, A. Gasco, J. Med. Chem. 2007, 50, 1449-1457.
23. D. Boschi, C. Cena, A. DiStilo, B. Rolando, P. Manzini, R. Fruttero, A. Gasco, Chem. Biodiversity 2010, 7, 1173-1182, and references therein.
24. A. Bhardwaj, Z. Huang, J. Kaur, E. E. Knaus, ChemMedChem 2012, 7, 62-67, and references therein.
25. M. Biava, G. C. Porretta, G. Poce, C. Battilocchio, S. Alfonso, M. Rovini, S. Valenti, G. Giorgi, V. Calderone, A. Martelli, L. Testai, L. Sautebin, A. Rossi, G. Papa, C. Ghelardini, L. Di Cesare Mannelli, A. Giordani, P. Anzellotti, A. Bruno, P. Patrignani, M. Anzini, J. Med. Chem. 2011, 54, 7759-7771.
26. R. C. Jin, J. Loscalzo, J. Blood Med. 2010, 1, 147-162.
27. A. deMel, F. Murad, A. M. Seifalian, Chem. Rev. 2011, 111, 5742-67.
28. G. E. Rovati, A. Sala, V. Capra, S. E. Dahlen, G. Folco, Trends Pharmacol. Sci. 2010, 31, 102-107.
29. D. F. Woodward, R. L. Jones, S. Narumiya, Pharmacol. Rev. 2011, 63, 471-538.
30. V. Capra, M. Bäck, S.S. Barbieri, M. Camera, E. Tremoli, G.E. Rovati, Med. Res. Rev. 2012, DOI:.
31. M. G. Bousser, P. Amarenco, A. Chamorro, P. S. M. Fischer, I. Ford, K. M. Fox, M. G. Hennerici, H. P. Mattle, P. M. Rothwell, A. DeCordoue, M. D. Fratacci, Lancet 2011, 377, 2013-2022.
32. E. Selg, C. Buccellati, M. Andersson, G. E. Rovati, M. Ezinga, A. Sala, A. K. Larsson, E. Ambrosio, L. Lastbom, V. Capra, B. Dahlen, A. Ryrfeldt, G. C. Folco, S. E. Dahlen, Br. J. Pharmacol. 2007, 152, 1185-1195.
33. Press release: European Medicines Agency recommends withdrawal of the marketing authorisations for lumiracoxib-containing medicines, London, December 13, 2007, http://www.emea.europa.eu/docs/en_ GB/document_library/Press_release/2009/11/WC500010995.pdf.
34. P. I. Pilans, R. A. Ghiculescu, G. Lampe, R. Wilson, R. Wong, G. A. Macdonald, J. Gastroenterol. Hepatol. 2012, 27, 1102-1105.
35. R. Morphy, Z. Rankovic, J. Med. Chem. 2005, 48, 6523-6543.
36. C. Ballatore, J. H. Soper, F. Piscitelli, M. James, L. Huang, O. Atasoylu, D. M. Huryn, J. Q. Trojanowski, V. M.-Y. Lee, K. R. Brunden, A. B. Smith III, J. Med. Chem. 2011, 54, 6969-6983.
37. G. A. Patani, E. J. LaVoie, Chem. Rev. 1996, 96, 3147-3176.
38. J. X. Qiao, P. Y. S. Lam, Synthesis 2011, 829-856.
39. W. J. Fanshawe, J. W. Epstein (American Cyanamid Company), US5001157, 1991.
40. T. Sardon, T. Cottin, J. Xu, A. Giannis, I. Vernos, ChemBioChem 2009, 10, 464-478.
41. A. Avdeef, J. E. A. Comer, S. J. Thomson, Anal. Chem. 1993, 65, 42-49.
42. A. Habib, G. A. FitzGerald, J. Maclouf, J. Biol. Chem. 1999, 274, 2645-2651.
43. B. T. Kinsella, Biochem. Soc. Trans. 2001, 29, 641-654.
44. R. A. Coleman, P. P. Humphrey, I. Kennedy, G. P. Levy, P. Lumley, Br. J. Pharmacol. 1981, 73, 773-778.
45. A. Krishna, A. Yadav J. Mol. Model. 2012, DOI:.
46. M. Ambrosio, F. Fanelli, S. Brocchetti, F. Raimondi, M. Mauri, G. E. Rovati, V. Capra, Cell. Mol. Life Sci. 2010, 67, 2979-2989.
47. V. Capra, A. Veltri, C. Foglia, L. Crimaldi, A. Habib, M. Parenti, G. E. Rovati, Mol. Pharmacol. 2004, 66, 880-889.
48. T. D. Warner, I. Vojnovic, D. Bishop-Bailey, J. A. Mithchell, FASEB J. 2006, 20, 542-544.
49. S. W. Rowlinson, J. R. Kiefer, J. J. Prusakiewicz, J. L. Pawlitz, K. R. Kozak, A. S. Kalguktar, W. C. Stallings, R. G. Kurumbail, L. J. Marnett, J. Biol. Chem. 2003, 278, 45763-45769.
50. M. Acemoglu, T. Allmendinger, J. Callieni, J. Cercus, O. Loiseleur, G. H. Sedelmeier, D. Xu, Tetrahedron 2004, 60, 11571-11586.
51. G. V. Born, M. J. Cross, J. Physiol. 1963, 168, 178-195.
52. P. Patrignani, M. R. Panara, M. G. Sciulli, G. Santini, G. Renda, C. Patrono, J. Physiol. Pharmacol. 1997, 48, 623-631.
53. G. E. Rovati, Trends Pharmacol. Sci. 1998, 19, 365-369.
54. P. J. Munson, D. Rodbard, Anal. Biochem. 1980, 107, 220-239.